← FDA Drug Approvals (Drugs@FDA)

PLUVICTO

NDA · New Drug Application · Sponsor: NOVARTIS · Approved 2022-03-23

Drug application

FDA Application #

NDA215833

Application type

New Drug Application

Brand name

PLUVICTO

Generic name

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

Active ingredients

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

NOVARTIS

Manufacturer

Novartis Pharmaceuticals Corporation

First approval

2022-03-23

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown